In this regard, it may be helpful to design novel therapies that benefit all mesothelioma patients that asbestos-induced mesotheliomas and mesotheliomas developing in carriers of germline BAP1 mutations share at least some of the same pathogenic mechanisms. Here, BAP1 is linked to mesothelioma.